Status:
COMPLETED
Evaluation of ClearLLab Leukemia and Lymphoma Panels
Lead Sponsor:
Beckman Coulter, Inc.
Conditions:
Leukemia-Lymphoma
Eligibility:
All Genders
Brief Summary
Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.
Detailed Description
Multi-center study of specimens from subjects presenting for flow cytometry immunophenotyping as part of their standard of care for hematological diseases work-up. Residual specimens will be tested us...
Eligibility Criteria
Inclusion
- Residual samples from patients with hematological abnormalities being evaluated by Flow Cytometry for the presence or absence of an abnormal population associated with a hematological malignancy. All subjects of any ethnicity, age and racial background will be included.
Exclusion
- Specimens and/or spent samples that are visibly hemolyzed
- Specimens and/or spent samples that are visibly clotted
- Specimens and/or spent samples collected in K2EDTA anticoagulant older than 24 hours from time of collection
- Specimens and/or spent samples collected in Heparin or ACD anticoagulant older than 48 hours from time of collection
- Samples with insufficient volume to complete the protocol tests
Key Trial Info
Start Date :
November 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 27 2018
Estimated Enrollment :
482 Patients enrolled
Trial Details
Trial ID
NCT03413644
Start Date
November 14 2017
End Date
April 27 2018
Last Update
July 13 2018
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
NeoGenomics Laboratories, Inc.
Fort Myers, Florida, United States, 33913
2
Calgary Laboratory Services
Calgary, Alberta, Canada, T2N 2T9
3
London Health Sciences Center
London, Ontario, Canada, N6A 5W9
4
Munich Leukemia Laboratory
Munich, Germany, 81377